Non-Hodgkin lymphoma (NHL) is a genetically heterogeneous disease with several oncogenic events implicated in the transformation of normal developing B lymphocytes. The objective of this study was to elucidate the signal transduction-based antitumor mechanism(s) of action for the anti-CD40 monoclonal antibody dacetuzumab (SGN-40) in NHL. We report that dacetuzumab activates two distinct proapoptotic signaling pathways, overcoming transformation events key to the pathogenesis of NHL. Dacetuzumab-mediated CD40 signaling constitutively activated the nuclear factor-jB and mitogenactivated protein kinase signaling pathways producing the sustained downregulation of B-cell lymphoma 6 (BCL-6), an oncoprotein implicated in lymphomagenesis. Loss of BCL-6 resulted in c-Myc downregulation and activation of a transcriptional program characteristic of early B-cell maturation, concomitant with reduced proliferation and cell death. In a second mechanism, dacetuzumab signaling induced the expression of the proapoptotic p53 family member TAp63a and downstream proteins associated with the intrinsic and extrinsic apoptotic machinery. Dacetuzumab was synergistic in combination with DNA-damaging chemotherapeutic drugs, correlating with TAp63a upregulation. Furthermore, dacetuzumab augmented the activity of rituximab in combination with multiple chemotherapies in the xenograft models of NHL. The ability of dacetuzumab signaling to circumvent oncogenic events and potentiate the activity of chemotherapy regimens provides a unique therapeutic approach to NHL.
Introduction
Non-Hodgkin lymphoma (NHL) is a genetically diverse subset of lymphomas originating from developing B cells transformed at various points in the normal B-cell maturation process. Oncogenic events occurring during VDJ recombination, somatic hypermutation or immunoglobulin (Ig) class switching prevent apoptosis of B cells not activated by antigen binding to B-cell receptor, maintaining cells in an artificial proliferative state. 1 Genes deregulated or inactivated in NHL include overexpression of B-cell lymphoma 6 (BCL-6), MYC or B-cell leukemia/ lymphoma 2 (BCL-2) by translocation within Ig loci, FAS mutation and loss or mutation of TP53. [2] [3] [4] [5] [6] A therapeutic approach capable of overcoming one or more of these oncogenic events, thereby reducing proliferation and resensitizing cells to apoptotic stimuli, would represent a significant advance in the treatment of NHL.
Lymphomas maintain many characteristics of the B-cell differentiation state at which they originated, including surface antigen expression. The tumor necrosis factor receptor (TNFR) superfamily member CD40 is expressed on B cells from the early pro-B phase through the fully differentiated memory B or secreting plasma cell phases. 7, 8 CD40 is a transmembrane protein with a large extracellular domain and a 42 amino acid cytoplasmic TNFR-associated factor interacting domain, which mediates downstream signaling through the nuclear factor kB (NF-kB), mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase and phospholipase Cg pathways. 9 CD40 signaling stimulated by binding to its trimeric ligand (CD40L or CD154) has an important role in normal B-cell differentiation, and mutation at the CD40L locus is responsible for X-linked hyper-IgM immunodeficiency syndrome. 10 Interaction of a naïve B cell with T-cell-expressed CD40L initiates proliferation and formation of germinal centers (GCs), whereas CD40-CD40L signaling in the GC light zone initiates a program to complete antibody affinity maturation and begin differentiation into mature plasma cells or memory B cells.
11
CD40 is an attractive oncology target for therapeutic intervention commonly expressed on lymphoid malignancies (NHL, multiple myeloma, Hodgkin lymphoma and acute lymphoblastic leukemia) as well as on a variety of carcinomas. 12 As with other TNFR superfamily members, signaling through CD40 activates pathways associated with both survival and apoptosis, which in NHL may produce different outcomes depending upon the lymphoma subtype. 13 A prolonged cell survival response is observed in chronic lymphocytic leukemia, whereas an anti-proliferative apoptotic response is observed in high-grade NHL such as diffuse large B-cell lymphoma (DLBCL). 14, 15 This differing outcome to CD40 signaling in lymphoid malignancies likely correlates with the stage in B-cell maturation at which transformation occurred.
At present, standard lymphoma therapy combines the anti-CD20 monoclonal antibody rituximab with chemotherapy regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) and ICE (ifosfamide, carboplatin and etoposide). 16, 17 A complementary approach to the treatment of NHL is the targeting of CD40 with monoclonal antibodies or with recombinant human CD40L, both of which have been shown to induce apoptosis in aggressive lymphomas. 12, 18 The humanized anti-CD40 monoclonal antibody dacetuzumab (SGN-40) mediates effector function activity, antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis, and is also able to directly induce apoptosis in cultured NHL cells. 19, 20 A comparison of dacetuzumab antitumor activity in severe combined immunodeficient mice versus natural killer cell-deficient severe combined immunodeficient-beige mice demonstrated that efficacy in certain lymphoma xenograft models is largely independent of effector function activity. 19 This finding suggested that dacetuzumab apoptotic signaling is an important component of its in vivo antitumor activity in NHL.
The goal of this study was to define non-effector function, signal transduction-based mechanisms of action by which dacetuzumab induces apoptosis in NHL cell lines. We have found that dacetuzumab stimulates signal transduction through CD40 on lymphoma cells, activating the NF-kB, ERK1/2 MAPK, JNK1/2 MAPK and p38 MAPK pathways in a sustained manner. Dacetuzumab signaling resulted in downregulation of BCL-6 oncoprotein and loss of c-Myc expression in GC-derived lymphoma cells, driving them from a transformed condition into a non-proliferative state resensitized to apoptotic stimuli. Furthermore, dacetuzumab upregulated the proapoptotic p53 family member, TAp63a and downstream proteins involved in both the extrinsic and intrinsic apoptotic pathways. Dacetuzumab chemosensitized lymphoma cells in vitro and in mouse xenograft models, potentiating the activity of standard NHL chemotherapeutic regimens. These data suggest dacetuzumabmediated signaling through CD40 can overcome key transformation events characteristic of NHL and improve the activity of existing rituximab-based combination NHL therapies.
Materials and methods

Cell lines, proliferation and apoptosis assays, and inhibitors
NHL cell lines Ramos, Toledo (ATCC, Manassas, VA, USA), RL, SU-DHL-4 and SU-DHL-8 (DSMZ, Braunschweig, Germany) were cultured in RPMI media þ 10% fetal bovine serum at 37 1C, 5% CO 2 . For cell proliferation assays, dacetuzumab was crosslinked with a Fcg-specific goat anti-human IgG F(ab 0 ) 2 fragment (Jackson ImmunoReasearch, Westgrove, PA, USA) (1:4 ratio), and plated onto cells in quadruplicate. Cells were treated for 72 h and then incubated for 8-24 h with 3 H-thymidine and DNA-incorporated radioactivity was measured with a TopCount NXT (PerkinElmer, Waltham, MA, USA). Cell death was measured using the annexin V-FITC apoptosis detection kit (EMD Biosciences, San Diego, CA, USA). Small-molecule signaling inhibitors U0126, JNK inhibitor VIII, p38 MAPK inhibitor III and NF-kB activation inhibitor (6-amino-4-(4-phenoxyphenethylamino)quinazoline) were obtained from EMD Biosciences, La Jolla, CA, USA.
Signaling studies and flow cytometry NHL cells (3 Â 10 5 cells/ml in RPMI þ 2% fetal bovine serum), were treated with crosslinked hIgG, dacetuzumab or rhCD40L (R&D Systems, Minneapolis, MN, USA), and collected by centrifugation. Cells were lysed in protein extraction buffer (50 mM Tris (pH ¼ 7.5), 1% NP-40, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA (pH ¼ 7.6), phosphatase inhibitors (EMD Biosciences San Diego, CA, USA) and protease inhibitor tablets (Roche, Basel, Switzerland)), then the cell lysates were centrifuged and the protein concentrations were measured. Activation of MAP kinase, AKT and NF-kB pathways was detected by western blotting with antibodies specific to phospho-p38 MAP kinase (Thr180/Tyr182), phospho-p44/42 MAP kinase (Thr202/Tyr204), phospho-JNK (Thr183/Tyr185), phospho-Akt (Ser473), IkB-a and IRF4 (Cell Signaling Technology, Beverly, MA, USA). Survival and apoptosis-related proteins were detected by western blotting with antibodies specific to BCL-6 (Abcam, Cambridge, MA, USA), p53, BID, b-actin (Cell Signaling Technology), BIM, c-Myc and p63 (BD Pharmingen, San Jose, CA, USA). Fas upregulation was measured by flow cytometry with anti-Fas-FITC-conjugated antibody and FACScan flow cytometer (BD Biosciences, San Jose, CA).
RT-PCR analysis
RNA was extracted with either RNA-Bee (Tel-Test, Friendswood, TX, USA) or RNeasy spin columns (Qiagen, Valencia, CA, USA). Reverse transcription of 5.0 mg RNA per reaction was conducted using the SuperScript III First-Strand Synthesis System (Invitrogen). The resulting cDNA was PCR amplified with RedTaq (Sigma, St Louis, MO, USA) and gene-specific primers: Immunohistochemistry Double-labeling immunohistochemistry was performed on formalin-fixed, paraffin-embedded Ramos xenograft tumor sections using the BondMax Autostainer (Leica Microsystems, Bannockburn, IL, USA). Following heat-induced antigen retrieval in EDTA, the Bond Polymer AP Red and Bond Intense R (for biotinylated antibodies) kits were used for antibody detection (Leica Microsystems). Tumor sections were blocked with Peroxidase Block (Dako, Carpinteria, CA, USA) and AvidinBiotin Block (Vector Laboratories, Burlingame, CA, USA). Sections were first labeled with mouse anti-human p63 at 0.07 mg/ml (Abcam), and detected using alkaline phosphataseFast Red. Next, sections were labeled with biotinylated goat anti-human Fc at 5 mg/ml (Jackson ImmunoResearch Laboratories), and detected with streptavidin-HRP/DAB. Tumor sections were imaged using an Axiovert 200M fluorescence microscope (Zeiss, Oberkochen, Germany), then TAp63a-specific staining was spectrally unmixed and quantitated using the Nuance multispectral imaging system (Cambridge Research & Instrumentation, Woburn, MA, USA).
NHL xenograft studies
Severe combined immunodeficient mice were implanted with Ramos or SU-DHL-8 cells ( Â 3) , i.p. Gemcitabine was dosed at 100 mg/kg (q4d Â 3), i.p. Tumor progression rates were reported as percent of mice having a tumor volume less than a defined end point value over time, using Kaplan-Meier plots. P-values were generated using the log-rank (Mantel-Cox) test. All animal studies are representative of two independent experiments.
Results
Dacetuzumab is a signaling antibody in NHL
Dacetuzumab produces an anti-proliferative and apoptotic response in cultured CD40
þ NHL cells, with increasing cell death occurring at 24 and 48 h after treatment in the Ramos cell line (Supplementary Figure 1a) . To elucidate the mechanisms behind dacetuzumab-mediated anti-proliferative and apoptotic activity, we tested the ability of dacetuzumab to stimulate cell signaling pathways following CD40 binding. Dacetuzumab, crosslinked with anti-human Fc antibody, activated the p42/44 (ERK1/2) and p38 MAP kinase pathways within 15 min in the RL lymphoma cell line relative to soluble dacetuzumab (Supplementary Figure 1b , lanes 5-7 versus lanes 2-4). NF-kB signaling was strongly activated by dacetuzumab as detected by loss of its negative regulatory protein IkB-a to proteasomal degradation. Dacetuzumab produced only a minor increase in signaling through the AKT pathway. The enhanced signal transduction observed with crosslinked dacetuzumab likely reflects the requirement for CD40 to multimerize on the cell surface and form active signaling complexes at the cytoplasmic domain through TNFR-associated factor proteins, a characteristic of TNFR superfamily members. 9 The signaling profile of dacetuzumab was very similar to trimeric human CD40 ligand in NHL cells (Supplementary Figure 1b , lane 11). Dacetuzumab produced a dose-dependent anti-proliferative response in Ramos cells, which correlated with its activation of ERK1/2 MAPK pathway signaling within a similar low ng/ml concentration range (Supplementary Figures 1a,c) .
Dacetuzumab signaling downregulates BCL-6 oncoprotein
In normal B cells, BCL-6 proto-oncogene mRNA is downregulated from peak levels in the hyperproliferative GC following CD40-CD40L signaling. 22 ,23 Therefore, we tested the hypothesis that dacetuzumab signaling would similarly downregulate BCL-6 in GC-derived lymphomas in which the BCL-6 gene is deregulated because of chromosomal translocation or mutation in the 5 0 -untranslated region. Three BCL-6-expressing NHL cell lines Ramos (Burkitt's lymphoma), SU-DHL-4 and RL (DLBCLs) and one BCL-6 À DLBCL cell line (Toledo) were treated with dacetuzumab or hIgG control, and the effect on BCL-6 protein level was examined by western blotting. Dacetuzumab treatment strongly downregulated BCL-6 protein in the three BCL-6 þ cell lines, almost completely reducing detectable protein by 48 h (Figure 1a ).
BCL-6 is implicated in lymphomagenesis and its sustained inhibition or downregulation may produce an anti-proliferative or apoptotic effect in GC lymphomas. 24 Therefore, we examined the kinetics of BCL-6 downregulation by dacetuzumab in the Ramos cell line. Dacetuzumab treatment suppressed BCL-6 protein levels in a sustained manner, with loss of expression first detected at 8 h after treatment and maintained beyond 48 h (Figure 1b) . Significantly, the onset of dacetuzumab-mediated apoptosis corresponded with the timing of BCL-6 downregulation (Supplementary Figure 1a) . Loss of BCL-6 protein expression by ubiquitin-mediated proteolysis has been reported following activation of the B-cell receptor and phosphorylation of sites within the PEST domains by ERK1/2 MAP kinases. 25 Examination of dacetuzumab-stimulated MAP kinase signaling kinetics revealed that the ERK1/2 pathway is constitutively activated, and that the level of signaling significantly increases over the course of several days, peaking at 43 h (Figure 1b ). Dacetuzumab also activated the p38 MAPK pathway in a sustained manner, whereas activation of JNK signaling was biphasic, reaching peaks of activity at 2 h followed by reactivation at 18-43 h. BCL-6 downregulation in normal B cells and some lymphomas has been reported following NF-kBmediated induction of IRF4, which transcriptionally represses BCL-6 expression. 23 Dacetuzumab activation of NF-kB signaling was also sustained over several days as detected by degradation of IkBa ( Figure 1b , lower panels). These data indicated that the downregulation of BCL-6 by dacetuzumab in NHL cell lines correlates with its ability to constitutively activate signaling through MAPK and NF-kB pathways.
To further link dacetuzumab signaling with BCL-6 downregulation, pharmacological inhibitors of MAPK pathway activation were tested for their ability to prevent dacetuzumab-mediated suppression of BCL-6 expression. Pretreatment with the MKK1/2 inhibitor (U0126) or JNK inhibitor VIII both partially blocked dacetuzumab-mediated BCL-6 degradation in Ramos and SU-DHL-4 cell lines ( Figure 1c ). Combining these two inhibitors produced a greater protection of BCL-6 protein in Ramos cells, suggesting the ERK1/2 and JNK MAPK pathways are important to the downregulation of BCL-6 by dacetuzumab. In contrast, inhibition of the p38 MAPK pathway failed to prevent BCL-6 downregulation. Next, we examined the significance of ERK1/2 MAPK signaling and BCL-6 downregulation for dacetuzumab-mediated apoptosis. The percent cell death induced by dacetuzumab was measured±U0126 in the BCL-6 þ lymphoma cell line RL (Figure 1d) . Dacetuzumab alone or with dimethyl sulfoxide carrier produced B50% total cell death, whereas RL cells pretreated with U0126 before addition of dacetuzumab had significantly reduced cell death (P ¼ 0.015; unpaired t-test). Increased RL cell viability correlated with block of ERK1/2 activation and stabilization of BCL-6 protein from degradation ( Figure 1d , lower panels). Similarly, in the SU-DHL-4 BCL-6 þ cell line U0126 produced a partial but significant (P ¼ 0.033) reduction of dacetuzumab-induced apoptosis (Supplementary Figure 2a) . IRF4 expression was not affected by dacetuzumab in the RL, HT and Ramos cell lines, whereas dacetuzumab weakly induced IRF-4 expression in SU-DHL-4 cells (Figure 1d and Supplementary Figure 2b) . Collectively these data show that constitutive activation of MAP kinase signaling and the subsequent downregulation of BCL-6 protein is an important mechanism of dacetuzumabinduced apoptosis in GC-derived lymphoma cell lines.
Dacetuzumab induces plasma cell differentiation genes and downregulates c-Myc
BCL-6 transcriptional repressor activity prevents the differentiation of normal GC B cells to plasma cells until somatic hypermutation is complete. 26, 27 Similarly in germinal center B-cell-like (GCB) subtype lymphomas, BCL-6 deregulation maintains cells in a hyperproliferative non-differentiated state, unresponsive to apoptotic stimuli such as DNA damage. 28 ,29
Therefore, we tested whether dacetuzumab-mediated downregulation of BCL-6 affected downstream differentiation and proliferation pathways in NHL cells. Reverse transcriptase-PCR was used to detect transcript levels of Blimp-1 and XBP-1, key transcription factors that control plasma cell differentiation, which are negatively regulated by BCL-6. In the three BCL-6 Table 1 ). These data suggest that BCL-6-expressing lymphoma cells can be driven by dacetuzumab-activated signaling into a hypoproliferative state with early characteristics of plasma cell differentiation via sustained downregulation of BCL-6, as hypothesized in Figure 2c .
Dacetuzumab upregulates the proapoptotic p53 family member, TAp63a
We have previously shown that the cytotoxic, anti-proliferative effect of dacetuzumab is not restricted to BCL-6 þ lymphoma cell lines, suggesting that dacetuzumab signaling can mediate antitumor response through mechanisms independent of BCL-6. CD40L signaling has been shown to regulate the expression of the p53-related transcription factor p73, 30 therefore, we examined the effect of dacetuzumab signaling on p53 family members. In Ramos cells, dacetuzumab produced a minor upregulation of p53 protein; however, a transcriptionally active form of p63 (TAp63a) was strongly induced by dacetuzumab at 18-72 h after treatment (Figure 3a ). Other NHL cell lines treated with dacetuzumab also showed inducible expression of TAp63a, with the amount of upregulation varying between cell lines (Figure 3b ). The highest induction was observed in Ramos and SU-DHL-8 cells, whereas SU-DHL-4 and RL had substantially lower TAp63a levels in response to dacetuzumab treatment. Endogenous TAp63a levels were below the lower limit of detection by western blotting. Transcriptional regulation of p63 isoforms reportedly involves the NF-kB pathway, and a single NF-kB-binding site has been identified within the p63 promoter. 31 To determine whether dacetuzumab activation of the NF-kB pathway is important for upregulation of TAp63a, we used a potent small-molecule NF-kB transcriptional activation inhibitor. Pretreatment of Ramos cells with NF-kB transcriptional activation inhibitor produced a dose-dependent decrease in TAp63a protein levels induced by dacetuzumab (Figure 3c ). Dacetuzumab stimulation of the NF-kB pathway is therefore required for complete upregulation of TAp63a.
Dacetuzumab has chemosensitization activity in NHL
p53 is frequently mutated in NHL cell lines (Supplementary  Table 1) , and dacetuzumab activation of TAp63a expression may partially restore p53-regulated proliferation and apoptosis checkpoints, such as response to cytotoxic drugs. To explore this possibility, dacetuzumab was evaluated in combination with DNA-damaging chemotherapeutic drugs in a NHL cell line with high levels of inducible TAp63a. Combination index analysis performed using the Chou-Talalay method 32 in the SU-DHL-8 cell line showed that dacetuzumab is moderately synergistic (CI 0.7-0.85) with chlorambucil, doxorubicin and etoposide and synergistic (CI 0.3-0.7) with bleomycin and carboplatin (Figure 4a and Supplementary Figure 3a) . These data indicate that dacetuzumab has chemosensitization activity. TAp63a expression is induced by a variety of chemotherapeutic drugs, 33 therefore we compared the ability of dacetuzumab to upregulate TAp63a with that of cytotoxic drugs. Dacetuzumab produced a far stronger induction of TAp63a in Ramos cells than either chlorambucil or gemcitabine at 20 mM or 20 nM, respectively ( Figure 4b, lanes 2-4 versus lanes 7 and 10) . The ability of dacetuzumab to induce TAp63a to higher levels than observed with chemotherapeutic drugs alone is one potential mechanism through which NHL cells are sensitized by dacetuzumab to cytotoxic damage. 
Dacetuzumab proapoptotic signaling mechanisms in NHL TS Lewis et al
Analysis of TAp63a-regulated genes in hepatocellular carcinoma has identified apoptosis-associated genes positively regulated by this transcription factor, including the death receptor Fas (CD95) and the proapoptotic BCL-2 family member Bim. 33 Fas was strongly upregulated on the surface of Ramos cells 24-48 h after treatment with dacetuzumab, consistent with the kinetics of TAp63a induction (Figure 4c ). In addition, dacetuzumab induced protein expression of Bim EL , Bim L and Bim S isoforms in Ramos cells 18-72 h after treatment (Figure 4d ). The Bim L isoform was upregulated by 2.8-fold above endogenous levels 72 h after treatment. A second proapoptotic BH3-only BCL-2 family member, Bid, was similarly induced by dacetuzumab (Supplementary Figure 3b) . Therefore, dacetuzumab positively regulates proapoptotic components in both the mitochondrial and death receptor pathways in NHL cell lines.
Dacetuzumab augments NHL chemotherapeutic regimens
Frontline, second-line and third-line DLBCL therapies consist of rituximab combined with CHOP (R-CHOP), ICE (R-ICE) and gemcitabine (R-Gem) chemotherapy regimens, respectively. To determine whether dacetuzumab potentiates standard lymphoma therapies in vivo, we evaluated the antitumor activity of dacetuzumab alone and in combination with R-CHOP, R-ICE and R-Gem in xenograft models of NHL. Kaplan-Meier tumor progression plots showing time to reach a tumor volume end point were used to present in vivo efficacy data in order to more accurately present statistical differences between the groups (Figures 5a-c) ; corresponding tumor volume plots for each study are provided in Supplementary Figure 4 . Dacetuzumab alone delayed the growth of subcutaneous Ramos tumors in the severe combined immunodeficient mice, and dacetuzumab had greater efficacy than rituximab, CHOP and ICE (Figures 5a and b) . The antitumor activity of R-CHOP was significantly improved when combined with dacetuzumab (D þ R-CHOP) in the Ramos model (P ¼ 0.0005), producing complete remissions in 8/10 animals ( Figure 5a ). Direct comparison of D-CHOP antitumor activity with that of R-CHOP demonstrated that dacetuzumab potentiates the activity of this chemotherapy regimen more strongly than rituximab in the Ramos model (P ¼ 0.0052). Furthermore, the efficacy observed in the D þ R-CHOP combination exceeded the dacetuzumab þ rituximab combination, suggesting that dacetuzumab-mediated chemosensitization of Ramos cells to CHOP, not augmented antibody-dependent cellular cytotoxicity effector activity, is the dominant mechanism. The non-steroidal cytotoxic components of CHOP were individually combined with dacetuzumab in the Ramos model, and the DNA-damaging drug cyclophosphamide was the most active agent (Supplementary Figure 5) . 
Dacetuzumab proapoptotic signaling mechanisms in NHL TS Lewis et al
Similarly, dacetuzumab potentiated the antitumor activity of ICE chemotherapy in the Ramos model, and D-ICE efficacy was greater than R-ICE (Figure 5b) . The antitumor activity of R-ICE was significantly improved in combination with dacetuzumab (D þ R-ICE) (Po0.0001), producing complete remissions in 3/10 animals. D þ R-ICE was administered in a single cycle, not allowing for a direct comparison with D þ R-CHOP efficacy, which was dosed in two cycles.
Gemcitabine alone produced durable complete remissions in the Ramos model, therefore we used a more chemoresistant DLBCL xenograft model, SU-DHL-8, to examine the activity of dacetuzumab in combination with R-Gem. SU-DHL-8 subcutaneous tumors are extremely aggressive with a tumor quadrupling time of B4 days. Dacetuzumab and rituximab dosed alone or in combination had minimal antitumor activity in this model, whereas gemcitabine delayed tumor progression without producing complete remissions (Figure 5c ). In combination with gemcitabine, dacetuzumab significantly improved the activity of this cytotoxic drug in vivo (P ¼ 0.0056). Furthermore, the efficacy of R-Gem was significantly improved in combination with dacetuzumab (D þ R-Gem) (Po0.0001), producing nondurable complete remissions in 7/9 animals.
The ability of dacetuzumab to augment the activity of chemotherapeutic regimens above the level achieved with rituximab suggests that dacetuzumab has in vivo chemosensitization activity. Furthermore, in vitro data indicated that in certain NHL cell lines TAp63a upregulation might be important for increased response to cytotoxic drugs (Figures 4a,b) . We therefore tested whether TAp63a is upregulated in vivo following dosing with dacetuzumab in the Ramos xenograft model. Immunohistochemistry staining of TAp63a was performed on Ramos tumor sections collected at 96 h after treatment with CHOP chemotherapy, control hIgG ± CHOP or dacetuzumab±CHOP ( Figure 5d ). As expected, dacetuzumab localized to the cell membrane of Ramos tumor cells, and the strongest anti-human Fc staining was detected at the tumor periphery or near blood vessels. TAp63a is a nuclear protein, and anti-TAp63a staining was detected in a small population of lymphoma cell nuclei in control groups. However, in the outer region of the Ramos tumors in which dacetuzumab staining was strongest, the number of lymphoma cells expressing nuclear TAp63a was distinctly elevated. Quantitation of the TAp63a chromaphore (fast red) with a multispectral imaging camera demonstrated that TAp63a levels were 43.5-fold higher in dacetuzumab treated tumors ± CHOP versus control treatment groups. The in vivo upregulation of TAp63a was confirmed by western blotting of Ramos tumor extracts (Figure 5d , lower panels). These data are direct evidence that dacetuzumab can stimulate signal transduction in lymphoma cells in vivo, inducing a protein with proapoptotic and chemosensitization activities.
Discussion
We previously showed that the anti-CD40 monoclonal antibody dacetuzumab triggers apoptosis in NHL cell lines. 19 In this study, we identified two mechanisms that contribute to dacetuzumab-mediated apoptosis and arrested proliferation in NHL cells; summarized in (Figure 6 ). We demonstrate that dacetuzumab is a signaling antibody, capable of sustained activation of the ERK1/2, JNK, p38 MAP kinase and NF-kB signaling cascades. Furthermore, constitutive dacetuzumab signaling through MAPK pathways downregulated BCL-6 expression in GC-derived lymphoma cells, inducing B-cell differentiation markers and ultimately triggering apoptosis. In addition, dacetuzumab signaling chemosensitized p53-mutant NHL cells concurrent with the upregulation of the p53 family member TAp63a. These observations provide a working model explaining how dacetuzumab signaling through CD40 produces an anti-proliferative, proapoptotic response in NHL cells as a single agent and in combination with cytotoxic drugs.
The POZ/zinc-finger transcriptional repressor BCL-6 is a key regulator of GC formation, B-cell differentiation and survival. 34 Activation of CD40-CD40L signaling in immature B cells in the GC activates a differentiation program to halt somatic hypermutation, class switching and proliferation and initiate B-cell maturation processes. By suppressing p53 checkpoint and the DNA-damage sensor ATR, BCL-6 protects developing B cells during somatic hypermutation and Ig class switching from apoptosis induced by DNA damage. 27, 28 Similarly, in GCderived lymphomas, including Burkitt's lymphoma, DLBCL and follicular lymphoma; BCL-6 maintains a non-differentiated hyperproliferative state analogous to a proliferating B cell in the GC. Mouse models mimicking the t(3;14) (q27:q32) translocation of BCL-6 found in certain DLBCL patients have been used to implicate BCL-6 deregulation in the formation of B-cell lymphomas. 35 ,36 BCL-6 is an appealing new target in the treatment of NHL, which is currently being targeted by inhibitory peptides, acetylation inhibitors, Hsp90 inhibitors and RNA interference. 37, 38 In a collaborative research effort, dacetuzumab has been shown to have greater cytotoxic activity against NHL cell lines of the BCL-6 þ GCB subtype than those of the BCL-6
À activated B-cell (ABC) subtype. 39 Our finding that dacetuzumab downregulates BCL-6 in a sustained manner suggests that anti-CD40 signaling antibodies may be a novel therapeutic approach to overcome this key oncogenic event in GCB subtype lymphomas.
The capability of CD40-mediated signaling to downregulate BCL-6 is likely due to both transcriptional and post-translational modification mechanisms. BCL-6 is reported to be transcriptionally downregulated following CD40L signaling in GC B cells and some lymphoma cell lines through NF-kB upregulation of the IRF4 transcription factor. 23 However, our observations indicate that BCL-6 downregulation by dacetuzumab can occur in the absence of IRF4 upregulation. Furthermore, mutations or chromosomal translocations blocking the IRF4 binding site within the BCL-6 promoter prevents downregulation of BCL-6 by CD40 signaling in a subset of DLBCL. BCL-6 phosphorylation within its PEST domains by ERK1/2 MAP kinases following activation of B-cell receptor signaling leads to its proteasomal degradation. 25 Our data shows that dacetuzumab-mediated apoptosis and downregulation of BCL-6 can be attenuated by inhibiting the ERK1/2 and JNK MAPK pathways, suggesting that dacetuzumab uses a post-translational mechanism to suppress BCL-6 expression. Therapeutically downregulating BCL-6 expression through sustained activation of MAPK signaling is advantageous in those GCB subtype DLBCLs in which the BCL-6 promoter is mutated and cannot be downregulated through IRF4 transcriptional repression alone.
Our data suggests that dacetuzumab downregulation of BCL-6 drives lymphoma cells into a hypoproliferative state resensitized to apoptotic stimuli analogous to the differentiation signal CD40-CD40L signaling triggers on GC B cells. MAPK signaling is often associated with mitogenic effects, nevertheless, there are documented instances in which sustained activation of MAPK signaling induces transformed cells to halt proliferation and undergo partial differentiation, 40, 41 and MEK1 has recently been identified as a tumor suppressor in a mouse lymphoma model. 42 The BCL-6-controlled transcription factors Blimp-1 and XBP-1 are important regulators of plasma cell differentiation, [43] [44] [45] [46] and both were found to be upregulated in BCL-6 þ cell lines following dacetuzumab treatment. Furthermore, repression of c-Myc by Blimp-1 is another important step in normal B-lymphocyte differentiation. 47 c-Myc is frequently deregulated in lymphomas and dacetuzumab signaling repressed c-Myc protein expression in BCL-6 þ cell lines, correlating with induced Blimp-1 expression. Interestingly, dacetuzumab signaling downregulated c-Myc in cell lines lacking a MYC-IG translocation as well as in a cell line having the t(8;14) MYC-IGH translocation. Blockade of BCL-6 and c-Myc expression by dacetuzumab provides a mechanism for how lymphoma cell lines of GC origin are driven into a non-proliferative state susceptible to apoptosis in the absence of prosurvival signaling.
The apoptotic activity of dacetuzumab is not restricted to BCL-6-deregulated lymphoma cell lines, therefore, other apoptotic signaling pathways are activated by dacetuzumab. We found that dacetuzumab upregulated the proapoptotic p53 family member TAp63a, a transcriptionally active isoform of p63, which has apoptotic activity when overexpressed and chemosensitizes carcinoma cells in vitro. 33, 48 Dacetuzumab induction of TAp63a is NF-kB pathway dependent; however, TAp63a is a target of ubiquitin-mediated proteolysis and dacetuzumab signaling may also upregulate this protein post translationally. 49 The abrupt upregulation of TAp63a from very low basal levels following dacetuzumab treatment is analogous to the upregulation of wild-type p53 in normal tissues responding to cytotoxic stress. Significantly, upregulation of nuclear TAp63a was detected in subcutaneously implanted Ramos tumor cells following dosing of dacetuzumab in mice, demonstrating that dacetuzumab signaling occurs in vivo at the tumor site. TAp63a positively regulates numerous genes involved in mitochondrial and death receptor apoptotic pathways, 33 including the dacetuzumab-induced proteins Fas and Bim. The proapoptotic BH3-only family members Bim and Bid were both upregulated by dacetuzumab, and this may mitigate the prosurvival advantage of BCL-2 overexpression in certain lymphomas.
The signaling characteristics of dacetuzumab may also account for its ability to sensitize lymphoma cell lines to chemotherapeutic drugs. We demonstrated that dacetuzumab is synergistic with a panel of cytotoxic DNA-damaging drugs in vitro and potentiated chemotherapeutic regimens in NHL xenograft models, improving the activity of rituximab in combination with CHOP, ICE and gemcitabine. This chemosensitization activity can be accounted for by mechanisms utilizing BCL-6 depletion and/or induced expression of p53 family members. Upregulation of TAp63a may substitute for p53 DNA damage response in lymphoma cells with mutant or deleted p53, improving the potency of DNA-damaging drugs. In addition, CD40-mediated downregulation of BCL-6 restores sensitivity to DNA damage in lymphoma cells, 27 and dacetuzumab may similarly sensitize lymphoma cells to cytotoxic drugs by constitutively downregulating BCL-6 expression. Interestingly, clinical data suggest that BCL-6 þ lymphoma patients did not benefit from the addition of rituximab to CHOP chemotherapy, whereas BCL-6 À patients showed improved response. 50 This raises the possibility an anti-CD40 signaling antibody, such as dacetuzumab, could provide additional benefit to BCL-6 þ NHL patients. In summary, we provide the first mechanistic data describing how dacetuzumab signaling through CD40 produces antiproliferative, apoptotic and chemosensitization responses in NHL cells. Dacetuzumab's ability to counteract oncogenic events implicated in lymphomagenesis distinguishes it from other NHL therapeutic antibodies with effector function based or ligand blocking mechanisms of action.
